ContraVir Pharmaceuticals Inc. (Nasdaq: CTRV) has begun enrolling the next dosing group in its head-to-head Phase 2a dose-escalation study of CMX157 to treat chronic hepatitis B. The stock price gained 38 cents to close at $2.34.
ContraVir Pharmaceuticals begin enrolling next dosing group
October 17, 2016 at 17:06 PM EDT
